Reuters Health News Summary
Following is a summary of current health news briefs.
Pharmacy chain Big Caring ends 0.9% higher after $155 million Malaysia IPO
Shares of Big Caring Group closed 0.9% higher in their market debut on Thursday after the Malaysian pharmacy chain raised 637.8 million ringgit ($155 million) in an initial public offering. Big Caring closed at 1.09 ringgit per share, above its IPO price of 1.08 ringgit, after trading between a low of 98 sen and a high of 1.19 ringgit. Malaysia's benchmark KLCI index closed 0.04% lower
Health Rounds: GLP-1 drugs tied to heart improvements in patients with obesity and heart failure
The benefits of widely used GLP-1 medications beyond weight loss continue to pile up as evidenced by a series of studies we cover today that were presented at the Obesity Week 2026 medical meeting in Washington. GLP-1 DRUGS MAY STRENGTHEN FAILING HEARTS
Novartis trims medium-term growth target, shares fall
Swiss drugmaker Novartis is targeting annual sales growth of 5% through 2031, the lower end of its previous five-year guidance, as looming patent expiries and a series of late-stage trial setbacks increase pressure on its blockbuster drugs. The new target, announced ahead of an investor event on Thursday, fell short of investor expectations relative to a 5%-6% annual growth range it set last year for 2025-2030.
Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial
Merck said on Friday that its experimental cancer drug helped patients with advanced stomach and esophageal cancers live longer than standard treatment options in a late-stage trial. Here are some details:
Sanofi's pill becomes first US-approved drug for rare neurological disorder
The US FDA on Wednesday approved Sanofi's oral drug venglustat, the first treatment approved for a type of rare genetic condition affecting the brain and nervous system. The drug, branded as Infilbray, is approved to treat type 3 Gaucher disease, the neurological variant of the disorder that causes certain fatty substances to accumulate in organs and tissues.
Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says
The impact of weight-loss drugs on UK grocery spending has surpassed £1 billion ($1.32 billion), as new pill formats and rising uptake among men accelerate their use, researcher Worldpanel by Numerator said on Thursday. UK households with at least one GLP-1 user spent more than £1 billion less on groceries than expected in the year after adoption compared with households without a GLP-1 user, Worldpanel said
Procter & Gamble targets up to $10 billion in productivity savings as costs stack up
Procter & Gamble is targeting up to $10 billion in productivity savings from fiscal years 2027-2030, Chief Financial Officer Andre Schulten said on Thursday, as the consumer goods bellwether strives to expand margins while coping with intense cost pressure. The company warned last month that rising raw material, energy and freight costs would take a bigger bite out of annual profit, even as resilient demand for its beauty and home-care products drove first-quarter sales.
US awards $47 million to 15 organizations to test chronic disease prevention in Medicare
The Trump administration on Friday announced $47 million in awards to 15 organizations under a Medicare initiative testing whether lifestyle-focused services can improve health and lower costs. US Health Secretary Robert F. Kennedy Jr. said, "Their (recipients) task is to test whether nutrition, physical activity, and other lifestyle interventions, and improve health and lower costs for people in original Medicare."
Sanofi weighs takeover of US drugmaker Insmed, Bloomberg News reports
Sanofi is weighing an acquisition of US drugmaker Insmed, Bloomberg News reported on Thursday, citing people familiar with the matter. Shares of Insmed, which has a market valuation of $26.28 billion according to LSEG data, were up 14%. Insmed did not immediately respond to a Reuters request for comment.
France on high alert for bird flu as seasonal wave spreads
France has increased its alert level for bird flu to the maximum after a seasonal spread of the disease was observed in wild birds in Europe, the government said on Thursday in its official journal. The measure, which will take effect on Friday, will involve restrictions such as confining poultry flocks.
Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines
Artificial intelligence has sped up early-stage drug development work at some of the world's largest pharmaceutical companies this year, cutting by as much as half the time it takes to produce new molecules and move them into the clinic, according to their top scientists. GSK, Bristol Myers Squibb, Novartis, Eli Lilly, Novo Nordisk, AstraZeneca and Sanofi all say they have moved beyond less glamorous tasks for AI like preparing regulatory filings. They are now using the technology for designing molecules, sorting out the most promising ones, and identifying safety risks.
Celldex ends eczema drug development after mid-stage trial failure
Celldex Therapeutics said on Thursday it would stop developing its experimental drug for eczema after the treatment failed to meet the main and key secondary goals of a mid-stage study. Shares of the company were down over 3% in extended trading.
US measles cases near 6,000 mark as outbreak worsens
The US Centers for Disease Control and Prevention on Friday reported 5,838 measles cases as of November 19, as the country battles its worst outbreak of the viral infection in decades. Measles cases in the US have climbed above 5,000 for the first time since 1991. Earlier this week, US lost its measles elimination status after 26 years
UnitedHealth sues US government over lowered Medicare Advantage star ratings
UnitedHealth Group sued the US government over its Medicare Advantage star ratings for 2027, saying the ratings threatened imminent harm by depriving the company of bonus payments and lowering benefits for patients. In a complaint filed late on Thursday, UnitedHealth said the Centers for Medicare & Medicaid Services improperly used 26 measures to calculate ratings for 45 contracts, saying the agency lacked statutory authority, did not provide a chance to object, or both.
Flesh-eating screwworm cases surge in US, keeping ranchers on alert
US infestations of New World screwworm, a parasitic fly that eats warm-blooded animals alive and threatens the cattle herd, have surged in unusually wet and warm weather in the Southwest, the US Department of Agriculture and state veterinarians said. Screwworms infested 64 cattle, dogs, horses and other domesticated animals this month, up from 34 in October and three in September, according to USDA data.
Ohio reports first pediatric flu death of 2026-27 season
Ohio reported its first flu-associated pediatric death of the 2026-27 season, involving a teenager under 18 from Ross County, the state health department said on Friday. The Ohio Department of Health said the state typically records between one and seven flu-associated pediatric deaths each season.
Analysis-Scientists are learning more about the rare Ebola virus in Congo outbreak
More than six months into a devastating Ebola outbreak in the Democratic Republic of Congo, scientists and medics are beginning to gain a better understanding of the rare Bundibugyo version of the virus, which they hope can help explain its rapid spread and, ultimately, stop it. There have been more than 11,000 cases and over 5,500 deaths so far, with the Bundibugyo virus spreading at double the pace of the 2014-2016 Ebola outbreak in West Africa, the largest on record. There are no licensed treatments or vaccines to fight it.
Erasca's pill shrinks hard-to-treat pancreatic and lung tumors in early-stage trial
Erasca said on Friday its experimental cancer pill shrank tumors in many patients with advanced pancreatic and lung cancers in an early-stage trial. Of 25 patients with pancreatic cancer taking a 32 mg daily dose of the drug, ERAS-0015, 44% saw tumors shrink significantly, Erasca said
AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco
AbbVie agreed to pay up to $2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech said on Thursday, marking an early-stage push by the drugmaker on next-generation bispecific therapies. Bispecific antibodies, a class of cancer medicines that bind two targets at once, have drawn increased interest from big drugmakers including Bristol Myers Squibb, Pfizer and Merck.
FDA sets up council for post-market review of vaccines, gene therapies
The US Food and Drug Administration said on Thursday it had established a new internal safety body within its biologics center, formalizing independent oversight of approved products such as vaccines, gene therapies and blood products once they reach the market. The CBER Safety Council will report directly to the director of the FDA's Center for Biologics Evaluation and Research, structurally separating post-market safety reviews from the offices responsible for approving those products, the agency said.
Judge blocks Trump's transgender-related limits on HIV funding
President Donald Trump's administration cannot impose restrictions barring healthcare providers that receive certain federal HIV-treatment funds from acknowledging the gender identity of their transgender patients or from providing them gender-affirming care, a federal judge ruled on Thursday. US District Judge William Young in Boston sided with a group of national HIV medical associations and healthcare providers that challenged grant funding conditions imposed by the administration last year after Trump signed an executive order prohibiting federal funding for what he calls "gender ideology."
Bausch + Lomb's eye-drop drug fails to reduce pain after laser surgery in trial
Bausch + Lomb said on Thursday its experimental eye-drop treatment failed to show a significant reduction in pain over the first 24 hours after laser eye surgery in a mid-stage study. However, the drug showed signs of benefit in secondary and exploratory analyses, including greater pain relief shortly after surgery and faster corneal healing.
Pennsylvania confirms eighth measles-related death amid US outbreak
The Pennsylvania Department of Health on Wednesday confirmed the state's eighth death associated with measles this year, the latest fatality linked to an outbreak of the highly contagious viral disease. The agency said the individual was an unvaccinated resident of Clinton County who had tested positive for measles. It did not immediately disclose the person's age or other details.
HK-listed Guangzhou Innogen signs over $1 billion licensing deal for diabetes drug
Hong Kong-listed Guangzhou Innogen Pharmaceutical said on Thursday it signed a licence agreement worth more than $1 billion with Arcera Life Sciences to commercialise its GLP-1 receptor agonist drugs used to treat patients with type 2 diabetes. The deal will allow Abu Dhabi-based Arcera to obtain regulatory approvals and commercialise the pharmaceutical product containing Efsubaglutide Alfa for human therapeutic use in selected countries in Africa, Latin America, the Middle East and Eastern Europe, Guangzhou Innogen said.
FDA to miss deadline on Savara's rare lung disease drug approval
Drug developer Savara said on Friday the US FDA would not meet its November 22 deadline to decide whether to approve the company's treatment for a rare lung disease, dealing a setback to the biotech firm. Shares of the company were down 16% in premarket trading.
Google News